BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 27553831)

  • 1. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
    Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma.
    Chen Y; Hu R; Li X; Shi Z; Tian H; Feng J; Yu S
    Pathol Res Pract; 2020 Oct; 216(10):153134. PubMed ID: 32853956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
    Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
    J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
    Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
    Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
    Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
    Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
    Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
    Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
    Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
    Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
    J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
    La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
    Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.
    Yan H; Qiu W; Koehne de Gonzalez AK; Wei JS; Tu M; Xi CH; Yang YR; Peng YP; Tsai WY; Remotti HE; Miao Y; Su GH
    Cancer Lett; 2019 Feb; 442():333-340. PubMed ID: 30447255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen-Presenting Intratumoral B Cells Affect CD4
    Bruno TC; Ebner PJ; Moore BL; Squalls OG; Waugh KA; Eruslanov EB; Singhal S; Mitchell JD; Franklin WA; Merrick DT; McCarter MD; Palmer BE; Kern JA; Slansky JE
    Cancer Immunol Res; 2017 Oct; 5(10):898-907. PubMed ID: 28848053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
    Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
    Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.